PDCD1 and ovarian cancer: In patients with platinum-sensitive, recurrent ovarian cancer who are gBRCA1/2 wild-type, the combination of PARPis with ivonescimab (AK112), bsAbs targeting both PD-1 and VEGF, has been investigated.